[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100366309":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":57,"collaborators":25,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":25,"enrollmentInfo":69,"targetDuration":25,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":25,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Population Health Research Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Higher Dose Unfractionated Heparin Treatment Period","ACTIVE_COMPARATOR","A centre wide policy of administering 100 U\u002Fkg bolus of intravenous unfractionated heparin (UFH) for elective percutaneous coronary intervention (PCI) procedures will be implemented during the Higher Dose UFH treatment period.",[13],"Drug: Higher Dose UFH",{"label":15,"type":10,"description":16,"interventionNames":17},"Lower Dose Unfractionated Heparin Treatment Period","A centre wide policy of administering 70 U\u002Fkg bolus of intravenous UFH for elective PCI procedures will be implemented during the Lower Dose UFH treatment period.",[18],"Drug: Lower Dose UFH",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Higher Dose UFH","Centre wide policy of administering 100 U\u002Fkg bolus of intravenous UFH for elective PCI procedures",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Lower Dose UFH","Centre wide policy of administering 70 U\u002Fkg bolus of intravenous UFH for elective PCI procedures",[15],[31],{"name":32,"affiliation":5,"role":33},"Sanjit Jolly, MD","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Jessica Tyrwhitt","CONTACT","905-521-2100","HD-PCI@phri.ca",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Hamilton Health Sciences, General Hospital","RECRUITING","Hamilton","Ontario","L8L 2X2","Canada","CA",{"type":50,"coordinates":51},"Point",[52,53],-79.84963,43.25011,{"lat":53,"lon":52},[56],{"name":32,"role":37,"phone":25,"phoneExt":25,"email":39},{"type":58,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100366309","higher-vs-lower-dose-heparin-for-pci-100366309",false,"NCT04049591","Higher vs. Lower Dose Heparin for PCI","A Randomized Trial of Higher vs. Lower Dose Heparin for PCI","HD-PCI","Inclusion Criteria:\n\n\\- Patients undergoing elective PCI\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Planned chronic total occlusion PCI\n* Non-resident precluding follow up through local registries\n\nHospital (Cluster) Eligibility Criteria\n\nHospitals will be eligible to participate if they meet the following criteria:\n\n* Submit PCI procedure data to a compatible registry that is able to provide data for the trial\n* Site agrees to manage patients as per the higher or lower dose heparin policy in place during the given crossover period","ALL","18 Years",{"count":70,"type":71},16000,"ESTIMATED","INTERVENTIONAL",[74],"NA","HD PCI is a multicenter, randomized, registry-based, cluster crossover design trial of higher dose versus lower dose heparin in patients undergoing elective percutaneous coronary intervention (PCI).",[77,78],"Cardiovascular Diseases","Percutaneous Coronary Intervention","2025-07-28",{"date":81,"type":82},"2025-07-31","ACTUAL",{"date":84,"type":82},"2022-03-02",{"date":86,"type":71},"2025-12",{"name":5,"class":6},1]